Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma

Overview of attention for article published in Clinical Cancer Research, December 2019

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

patent: 1 patent

Readers on

mendeley: 31 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 22,294 followers.

"CD45-targeted ARC therapy is well-tolerated at doses up to at least 32 Gy to the liver. Objective responses& long-term remissions were observed in patients with r/r lymphoma. These data validate continued evaluation of anti-CD45 ARCs in lymphoma" $…

In the December issue: Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma - pick up complimentary copies of the Journal in @AACR booth 222 at #ASH2019. https://t.co/dIVET9Ir1m https://t.co/QaHGvv9llQ

Phase I Study of a CD45-Targeted Antibody–Radionuclide Conjugate for High-Risk Lymphoma https://t.co/VnoeAuSMa9

Study of a CD45-Targeted Antibody-Radionuclide Conjugate for High-Risk #Lymphoma. https://t.co/0Sg4tvAE0O

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.